Transaction · 0001628280-26-001241

Burnett Patrick

Burnett Patrick, SR, reported an open-market or private sale at Arcutis Biotherapeutics, Inc. involving 2490.000000 shares for an estimated $72165.68. Reported holdings after the transaction were 94120.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SSR
ARQTArcutis Biotherapeutics, Inc.
Filing timeJan 07
Trade dateJan 05, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
…
Pre-filing
…
Returns since
…

ARQT price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
ARQT since 2026-01-07Filed 240 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001628280-26-001241
Common Stock
Transaction date
Jan 05, 2026
Filed Jan 07, 2026, 10:46 PM · 2d delay
Shares
2.49k sh
$2.89k per share
Estimated value
-$7.21M
Computed from shares × price
Holdings after
94.1k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Cluster Selling Direct Ownership Large Sale Repeat Seller 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

See Remarks

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.

  2. F2

    The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $28.77 to $29.19, inclusive. The Reporting Person hereby undertake…

Original filing · 0001628280-26-001241
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

ARQT